DGAP-News: AiCuris Anti-infective Cures GmbH / Key word(s): Conference
AiCuris celebrates its 10th Anniversary hosting a Mini-Symposium on
Challenges and Breakthroughs of Anti-infective Therapies at the
BIO-Europe(R) 2016
28.10.2016 / 09:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
AiCuris celebrates its 10th Anniversary hosting a Mini-Symposium on
Challenges and Breakthroughs of Anti-infective Therapies at the
BIO-Europe(R) 2016
Wuppertal, Germany, October 28, 2016 - AiCuris Anti-infective Cures GmbH, a
leading company in the discovery and development of drugs against
infectious diseases, today announced, that it will host in cooperation with
the BIO Clustermanagement NRW GmbH a press conference and mini-symposium to
celebrate its 10th Anniversary at the BIO-Europe(R) 2016 - 22nd Annual
International Partnering Conference being held November 7-9, 2016 in
Cologne, Germany. The mini-symposium titled "Challenges and breakthroughs
of anti-infective therapies - 10 years of AiCuris!" will take place on
Tuesday, November 8th from 11:00 am to 12:00 noon at the BIO.NRW booth 100.
During this event, renowned experts in infectious diseases will discuss
today's and future needs in the treatment of infectious diseases as well as
innovative approaches that address urgent medical needs, e.g. in terms of
new modes of action.
Presentations at the mini-symposium include:
- Short introduction: Anti-infective therapy and resistance issues
Prof. Dr. Theodor Dingermann, Goethe-University Frankfurt, Institute
for Pharmaceutical Biology
- Current challenges in anti-infective therapies from a clinician's
perspective
Prof. Dr. med. Andrew Ullmann, University Hospital Würzburg, Department
Infectious Diseases
- AiCuris: 10 years of successful R&D in anti-infective therapy
Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures GmbH
Prof. Dr. Theodor Dingermann will also moderate the mini-symposium.
Anti-infectives, including antibiotics and antivirals have greatly
increased human life expectancy since 1932 with the first commercially
available antibacterial from Bayer Laboratories. "The current medical
standards for the treatment and prevention of infections, e.g. in intensive
care or transplantations, are unthinkable without anti-infectives. However,
multi-drug resistant pathogens are now omnipresent and antibiotics, the
former wonder drugs, are losing their effectiveness," commented Dr. Holger
Zimmermann, CEO of AiCuris Anti-infective Cures GmbH. "Since our foundation
as a spin out from Bayer in 2006, AiCuris has established itself as a
powerhouse for anti-infectives R&D. The company strives to make a
difference and is dedicated to develop novel resistance-breaking antiviral
and antibacterial agents that address high medical needs."
The AiCuris portfolio today comprises seven clinical development programs
including letermovir, a prophylactic treatment against human
cytomegalovirus (HCMV) in bone marrow transplant patients, licensed to
Merck & Co. (MSD) in 2012. Last week, AiCuris announced that letermovir met
the primary endpoint in a pivotal phase 3 study. Pritelivir, a helicase-
primase inhibitor, being developed to treat herpes simplex virus Type 1
(HSV-1) and Type 2 (HSV-2) infections has successfully completed phase 2
clinical trials as an oral formulation against genital herpes and, in its
topical form targeted against labial herpes, a clinical phase 1 study.
Other preclinical and clinical programs include small molecules against
HCMV, hepatitis B virus (HBV), adenovirus, resistance breaking hospital
antibiotics and two immune modulators.
In addition, AiCuris will present its recent successes and expected future
developments in a company presentation on November 9th from 12:10 at the
conference in room Room 1 / Rheinsaal 1. Companies interested in meeting
with AiCuris at BIO-Europe(R) are asked to request a meeting through the
event's partneringONE(R) online system or to contact business@aicuris.com.
The Company will also be available to the media for interviews and
background discussions. Please contact MC Services at caroline.bergmann@mc-
services.eu to arrange for media meetings.
About BIO-Europe(R)
BIO-Europe(R) is the preeminent partnering conference for the life
sciences, bringing together international decision makers from the
biotechnology, pharmaceutical and financial sectors, offering networking
opportunities, workshop and panel participation, a high profile exhibition,
and private, prescheduled one-on-one meetings. The BIO-Europe(R) 2016
partnering event is expected to draw over 3,500 industry attendees for
three days of high level networking, representing upwards of 1,900
companies from over 50 countries.
About AiCuris Anti-infective Cures GmbH
AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the
discovery and development of drugs against infectious diseases. The
company's majority investor is SANTO Holding. The company is developing
drugs for the treatment of viruses such as human cytomegalovirus (HCMV),
herpes simplex virus (HSV), hepatitis B virus (HBV), and adenoviruses. In
the field of antibacterials, AiCuris seeks to develop innovative treatment
options for life-threatening, (multidrug)-resistant hospital-treated
pathogens. In 2012, AiCuris signed a license agreement with Merck & Co
(MSD), one of the largest agreements of its kind in the European biotech
industry. The agreement covers the development and commercialization of
novel drug candidates against HCMV. Letermovir, the most advanced compound
under this agreement, met primary endpoints in a pivotal phase 3 clinical
trial in patients undergoing bone marrow transplantation.
<pre>
Contact: Media Relations
AiCuris Anti-infective Cures MC Services AG
GmbH
Katja Woestenhemke Anne Hennecke
Friedrich-Ebert-Str. 475/Geb. Kaiser-Friedrich-Ring 5
302
42117 Wuppertal 40545 Düsseldorf
Phone +49 202 317 63 0 Phone +49 211 529 252 22
Fax +49 202 317 63 1601 Fax +49 211 529 252 29
Email business@aicuris.com Email anne.hennecke@mc-services.eu
Web www.aicuris.com Web www.mc-services.eu
</pre>
---------------------------------------------------------------------------
28.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
515539 28.10.2016
DGAP-News: AiCuris celebrates its 10th Anniversary hosting a Mini-Symposium on Challenges and Breakthroughs of Anti-infective Therapies at the BIO-Europe(R) 2016
| Quelle: EQS Group AG